3406 related articles for article (PubMed ID: 19092648)
1. Antiplatelet intervention in acute coronary syndrome.
Arora RR; Rai F
Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
3. API expert consensus document on management of ischemic heart disease.
Association of Physicians of India
J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
[TBL] [Abstract][Full Text] [Related]
4. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology.
Alexander KP; Newby LK; Cannon CP; Armstrong PW; Gibler WB; Rich MW; Van de Werf F; White HD; Weaver WD; Naylor MD; Gore JM; Krumholz HM; Ohman EM; ;
Circulation; 2007 May; 115(19):2549-69. PubMed ID: 17502590
[TBL] [Abstract][Full Text] [Related]
5. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative.
Mehta RH; Roe MT; Chen AY; Lytle BL; Pollack CV; Brindis RG; Smith SC; Harrington RA; Fintel D; Fraulo ES; Califf RM; Gibler WB; Ohman EM; Peterson ED
Arch Intern Med; 2006 Oct; 166(18):2027-34. PubMed ID: 17030838
[TBL] [Abstract][Full Text] [Related]
6. Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience.
Banihashemi B; Goodman SG; Yan RT; Welsh RC; Mehta SR; Montalescot G; Kornder JM; Wong GC; Gyenes G; Steg PG; Yan AT;
Am Heart J; 2009 Dec; 158(6):917-24. PubMed ID: 19958857
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III.
Cohen M; Diez JE; Levine GN; Ferguson JJ; Morrow DA; Rao SV; Zidar JP; ;
J Invasive Cardiol; 2007 Dec; 19(12):525-38; quiz 539-40. PubMed ID: 18180524
[TBL] [Abstract][Full Text] [Related]
8. Interpretation of new treatment guidelines for non-ST-segment elevation acute coronary syndromes: "ischemia-guided" versus "early invasive" strategies.
Boden WE
Minerva Cardioangiol; 2003 Oct; 51(5):447-61. PubMed ID: 14551515
[TBL] [Abstract][Full Text] [Related]
9. Strategies for optimizing outcomes in the NSTE-ACS patient The CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report.
Cohen M; Diez J; Fry E; Rao SV; Ferguson JJ; Zidar J; Levine G; Shani J
J Invasive Cardiol; 2006 Dec; 18(12):617-39. PubMed ID: 17197714
[TBL] [Abstract][Full Text] [Related]
10. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
Ferguson JJ; Wilson JM; Diez J
Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
[TBL] [Abstract][Full Text] [Related]
11. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
12. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
[TBL] [Abstract][Full Text] [Related]
14. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
[TBL] [Abstract][Full Text] [Related]
15. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
Silva MA; Donovan JL; Gandhi PJ; Volturo GA
Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
[TBL] [Abstract][Full Text] [Related]
16. Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough.
Tcheng JE
J Interv Cardiol; 2006 Oct; 19(5):456-63. PubMed ID: 17020571
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe.
Thomas D; Giugliano RP
J Cardiovasc Pharmacol; 2008 May; 51(5):425-33. PubMed ID: 18418272
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
[TBL] [Abstract][Full Text] [Related]
19. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
